
Aisha Elsharkawy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11942896/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017. JAMA Oncology, 2019, 5, 1749.	7.1	1,691
2	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology and Hepatology, 2020, 5, 245-266.	8.1	823
3	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. Lancet HIV,the, 2019, 6, e831-e859.	4.7	341
4	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. New England Journal of Medicine, 2020, 382, 1166-1174.	27.0	160
5	Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepatic Medicine: Evidence and Research, 2017, Volume 9, 17-25.	2.5	129
6	Mapping geographical inequalities in access to drinking water and sanitation facilities in low-income and middle-income countries, 2000–17. The Lancet Global Health, 2020, 8, e1162-e1185.	6.3	91
7	Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 1779-1801.	13.7	72
8	Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1624-1630.	2.8	71
9	Anemia prevalence in women of reproductive age in low- and middle-income countries between 2000 and 2018. Nature Medicine, 2021, 27, 1761-1782.	30.7	60
10	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. Lancet HIV,the, 2021, 8, e633-e651.	4.7	56
11	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. Journal of Hepatology, 2018, 68, 691-698.	3.7	50
12	HCV in Egypt, prevention, treatment and key barriers to elimination. Expert Review of Anti-Infective Therapy, 2018, 16, 345-350.	4.4	43
13	Coinfection with hepatitis C virus and schistosomiasis: Fibrosis and treatment response. World Journal of Gastroenterology, 2013, 19, 2691.	3.3	39
14	Improvement of glycemic state among responders to Sofosbuvirâ€based treatment regimens: Single center experience. Journal of Medical Virology, 2017, 89, 2181-2187.	5.0	39
15	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. Journal of Interferon and Cytokine Research, 2015, 35, 49-54.	1.2	37
16	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut, 2019, 68, 721-728.	12.1	34
17	miRNA-101-1 and miRNA-221 expressions and their polymorphisms as biomarkers for early diagnosis of hepatocellular carcinoma. Infection, Genetics and Evolution, 2017, 51, 173-181.	2.3	32
18	Subnational mapping of HIV incidence and mortality among individuals aged 15–49 years in sub-Saharan Africa, 2000–18: a modelling study. Lancet HIV,the, 2021, 8, e363-e375.	4.7	32

AISHA ELSHARKAWY

#	Article	IF	CITATIONS
19	Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Review of Gastroenterology and Hepatology, 2017, 11, 773-778.	3.0	27
20	FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab Journal of Gastroenterology, 2016, 17, 78-83.	0.9	25
21	Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. Hepatology International, 2018, 12, 75-82.	4.2	24
22	Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000–17. The Lancet Global Health, 2020, 8, e1038-e1060.	6.3	23
23	Fibroscan of chronic HCV patients coinfected with schistosomiasis. Arab Journal of Gastroenterology, 2013, 14, 109-112.	0.9	20
24	Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. European Journal of Gastroenterology and Hepatology, 2020, 32, 1008-1016.	1.6	19
25	Novel scores combining AFP with nonâ€invasive markers for prediction of liver fibrosis in chronic hepatitis C patients. Journal of Medical Virology, 2018, 90, 1080-1086.	5.0	18
26	Value of <scp>E</scp> gyâ€ <scp>S</scp> core in diagnosis of significant, advanced hepatic fibrosis and cirrhosis compared to aspartate aminotransferaseâ€toâ€platelet ratio index, <scp>FIB</scp> â€4 and <scp>F</scp> orns' index in chronic hepatitis <scp>C</scp> virus. Hepatology Research, 2015, 45, 560-570.	3.4	17
27	Interferon gamma and interleukin 8 gene polymorphisms in patients with hepatitis C virus related oral lichen planus. Archives of Oral Biology, 2018, 96, 189-194.	1.8	15
28	Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment. Arab Journal of Gastroenterology, 2013, 14, 94-98.	0.9	13
29	Comparing the efficiency of Fibâ€4, Egyâ€score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. Journal of Medical Virology, 2018, 90, 1106-1111.	5.0	13
30	Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens. Journal of Interferon and Cytokine Research, 2018, 38, 129-136.	1.2	13
31	Clinical impact of serum α-fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2019, 31, 1129-1134.	1.6	13
32	Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. Expert Review of Anti-Infective Therapy, 2020, 18, 637-642.	4.4	13
33	Diagnostic accuracy of acoustic radiation force impulse elastography (ARFI) in comparison to other non-invasive modalities in staging of liver fibrosis in chronic HCV patients: single-center experience. Abdominal Radiology, 2019, 44, 2751-2758.	2.1	12
34	DAAs therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. Expert Review of Gastroenterology and Hepatology, 2019, 13, 693-698.	3.0	8
35	High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. European Journal of Castroenterology and Hepatology, 2018, 30, 1194-1199.	1.6	7
36	Genetic Variants in Nicotinamide-N-Methyltransferase (NNMT) Gene are Related to the Stage of Non-Alcoholic Fatty Liver Disease Diagnosed by Controlled Attenuation Parameter (CAP)-FibroScan. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 265-272.	0.9	7

AISHA ELSHARKAWY

#	Article	IF	CITATIONS
37	Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. Acta Tropica, 2017, 176, 283-287.	2.0	6
38	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. European Journal of Gastroenterology and Hepatology, 2018, 30, 882-887.	1.6	6
39	IP-10 Serum Level in Chronic Hepatitis C Virus Patients: Relation to Fibrosis and Response to Combined Interferon/Ribavirin Therapy. Journal of Interferon and Cytokine Research, 2015, 35, 649-653.	1.2	5
40	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. Expert Review of Gastroenterology and Hepatology, 2019, 13, 1009-1016.	3.0	5
41	Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2020, 114, 232-240.	1.8	5
42	Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets, 2021, 32, 383-390.	2.3	5
43	Fibrosis regression following hepatitis C antiviral therapy. World Journal of Hepatology, 2022, 14, 1120-1130.	2.0	5
44	Egy-score as a noninvasive score for the assessment of hepatic fibrosis in chronic hepatitis C: A preliminary approach. Saudi Journal of Gastroenterology, 2014, 20, 170.	1.1	4
45	Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients. Arab Journal of Gastroenterology, 2017, 18, 210-215.	0.9	3
46	HCV/HIV coinfected Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 227-232.	1.8	3
47	Assessment of hepatic fibrosis by fibroscan in egyptian chronic hemodialysis patients with chronic Hepatitis C (genotype 4): A single-center study. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2017, 28, 764-773.	0.3	3
48	Highly Sensitive Serum miRNA Panel for the Diagnosis of Hepatocellular Carcinoma in Egyptian Patients with HCV-Related HCC. Laboratory Medicine, 2022, 53, 523-529.	1.2	3
49	Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection, 2020, 48, 913-922.	4.7	2
50	The oral microbiome of treated and untreated chronic HCV infection: A preliminary study. Oral Diseases, 2023, 29, 843-852.	3.0	2
51	Evaluation of red cell distribution width to platelet ratio as a novel non-invasive index for predicting hepatic fibrosis in patients with chronic hepatitis C. Arab Journal of Gastroenterology, 2021, 22, 6-11.	0.9	1
52	Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, .	1.6	1
53	OUP accepted manuscript. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2021, , .	1.8	0
54	Perceived stigma and healthcare services in healthcare settings among people living with HIV in Egypt: a qualitative study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 868-873.	1.8	0

#	Article	IF	CITATIONS
55	Role of liver biopsy versus non-invasive biomarkers for diagnosis of significant fibrosis and cirrhosis: a web-based survey. Egyptian Liver Journal, 2021, 11, .	0.6	0